Results 61 to 70 of about 1,292 (153)

Pyoderma Gangrenosum as the First Manifestation of Inflammatory Bowel Disease: A Case Report

Case Reports in Gastrointestinal Medicine, Volume 2026, Issue 1, 2026.
Approximately 50% of patients with inflammatory bowel disease (IBD) exhibit extraintestinal manifestations, among which skin and mucosal lesions are common. However, pyoderma gangrenosum occurs in only 1%‐2% of IBD patients. We report the case of a 23‐year‐old male patient who was admitted to the hospital with pyoderma gangrenosum that was unresponsive
Nam Hoai Nguyen, Tan Thi Tran, Trang Thu Khuc, Yen Thi Lo, Ha Thi-Ngoc Doan, Hieu Van Nguyen, Long Cong Nguyen, Marcel Cc Machado   +7 more
wiley   +1 more source

Progressive Linear Bullous Eruption in a Young Athlete: A Diagnostic Challenge

Journal of Paediatrics and Child Health, Volume 62, Issue 5, Page 894-896, May 2026.
Chon‐Wai Jeremy Chan, Matthew Verheyden, Ashwati Krishnan Varikara, Michael Chang, John Relic   +4 more
wiley   +1 more source

ROS‐Scavenging Multifunctional Microneedle Patch Facilitating Wound Healing

Advanced Healthcare Materials, Volume 14, Issue 31, December 8, 2025.
A reactive oxygen species (ROS) scavenging and immunomodulatory microneedle patch based on hyaluronic acid methacrylate (HaMA) and Flightless I (Flii)‐siRNA‐laden arginine functionalized poly (β‐amino ester)/alginate particles is developed for chronic wound healing applications.
Mahshid Kharaziha, Sahar Salehi, Mahshid Shokri, Seyed Mohsen Ahmadi Tafti, Thomas Scheibel   +4 more
wiley   +1 more source

Differential risks of venous thromboembolic events in pemphigus and pemphigoid diseases

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page e256-e258, April 2026.
Maren E. Buenning, Sri Harini Purusothaman, Svea Symannek, Philip Curman, Khalaf Kridin, Enno Schmidt, Katja Bieber, Ralf J. Ludwig   +7 more
wiley   +1 more source

Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase (PI3K) inhibitors reduce vascular inflammation in vitro and in vivo

British Journal of Pharmacology, Volume 182, Issue 24, Page 6028-6042, December 2025.
Background and Purpose Endothelial cells play central roles in increasing vascular permeability and leukocyte recruitment. Therapeutic approaches for treating endothelial cell barrier dysfunction to reduce unwanted fluid accumulation in tissues are limited.
Hiba Chaudhry, Ali A. Zarban, Silvia Cellone Trevelin, Xenia Kodji, Camilla Cerutti, Xiaoqing Xiong, Fulye Argunhan, Ajay M. Shah, Anne J. Ridley, Susan D. Brain   +9 more
wiley   +1 more source

Mechanobullous form of epidermolysis bullosa acquisita: Insights into disease mechanisms as inferred by response to rituximab, but not to JAK inhibitors

JEADV Clinical Practice
Epidermolysis bullosa acquisita (EBA) is a rare autoimmune blistering disease associated with IgG autoantibodies directed against type VII collagen. Different clinical forms have been described, including the classical mechanobullous variant resembling ...
L. Gueissaz, A. Junge, R. Wolf, C. Schlapbach, L. Feldmeyer, L. Borradori   +5 more
doaj   +1 more source

A viral infection usually seen after feast of sacrifice: Human orf, in this case accompanied with erythema multiforme

Medicine Science, 2018
Orf is an infectious disease caused by an epitheliotrophic double stranded deoxyribonucleic acid parapoxvirus which primarily affects sheep and goats but humans can also be infected by contact with infected animals.
Sezin Ficicioglu
doaj   +1 more source

Epidermolysis bullosa acquisita

Vestnik dermatologii i venerologii, 2015
The article describes present-day information on the pathogenesis, clinical picture, treatment and differential diagnostics of epidermolysis bullosa acquisita, an autoimmune skin disease caused by the production of anti-Type VII collagen autoantibodies and manifested mainly by subepidermal blisters and erosions.
V. V. Chikin, L. F. Znamenskaya, M. A. Nefedova, V. A. Charikov   +3 more
openaire   +3 more sources

A Case of Palmoplantar Vesiculobullous Lesions

JEADV Clinical Practice, Volume 5, Issue 1, Page 315-318, March 2026.
Ali Abid, Kelvin Truong, Jing Jing Li, Artiene Tatian   +3 more
wiley   +1 more source

The Risk of Immune‐Mediated Skin Disease Under Dipeptidyl‐Peptidase IV Inhibitor: A Global Population‐Based Study

International Journal of Dermatology, Volume 65, Issue 2, Page 356-358, February 2026.
Noor Mruwat, Noga Givon‐Lavi, Ralf J. Ludwig, Khalaf Kridin   +3 more
wiley   +1 more source